Kolistimetatnatrium Noridem (Colistimethate Sodium)

After inhalation, colistimethate sodium is converted to colistin, which binds to the lipopolysaccharide and phospholipid layers of Gram‑negative bacterial membranes. This binding disrupts membrane integrity, increases permeability, and ultimately kills the bacteria.

The dosage and frequency are determined by the prescribing clinician based on the patient’s age, weight, severity of infection, and renal function. The prescriber will specify the exact inhalation volume and schedule.

Safety data for colistimethate sodium in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and under medical supervision.

Enquiries are submitted via the product page on gnhindia.com, where you enter the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Inhaled colistimethate sodium delivers high local concentrations directly to the airways, often achieving better bacterial eradication than systemic antibiotics while reducing systemic exposure. Compared with other inhaled antibiotics such as tobramycin, colistin may be preferred for strains resistant to aminoglycosides.

The product should be stored at room temperature, below 25 °C, in its original packaging. Keep it away from moisture and direct sunlight. Do not freeze. Reconstituted solution should be used within the time frame specified in the label.

It is administered by nebulization using a compatible inhalation device. The patient inhales the prescribed volume of the reconstituted solution, typically once or twice daily, as directed by the healthcare professional.

Serious adverse events include respiratory failure, severe bronchospasm, anaphylactic reactions, nephrotoxicity from systemic absorption, and neurotoxicity such as seizures or paresthesia. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to colistimethate sodium or any component of the formulation should avoid its use. It is also contraindicated in individuals with severe renal impairment where systemic exposure could be hazardous, unless closely monitored.